Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Brexpiprazole ODT vs Conventional Tablet
NCT03902574Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brexpiprazole orally disintegrating tablet (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum (Peak) Plasma Concentration and Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t. Started Mar 2019; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
Beyond the preview
Go deeper on NCT03902574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902574.